年間契約型情報サービス

La Merie Publishingレポートの定額購読

Flat-Rate Subscription to La Merie Publishing Reports

発行 La Merie Publishing 商品コード 276496
出版日 年間契約型情報サービス ページ情報 英文 1 Year Access to All Reports
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
La Merie Publishingレポートの定額購読 Flat-Rate Subscription to La Merie Publishing Reports
出版日: 年間契約型情報サービス ページ情報: 英文 1 Year Access to All Reports
概要

当年間情報サービスでは、La Merie Publishing発行による、およびオンラインストアに記載されている既存・新規の全レポートへの1年を通じたアクセスをご提供いたします。

La Merie Publishing発行レポートへの定額料金制アクセスの特徴

  • 動的コンテンツ(年間50回以上のアップデートおよびニュースリリース)。
  • 購読および新規リリースに応じてPDF形式のレポートを便利なEメールでお届けします。
  • 癌、バイオシミラー、抗体、タンパク質およびワクチンを広範に取り扱っています。
  • 個別の購入よりも大幅に節約できます。

フルレポート:標的、パイプライン、企業および技術の詳細な説明と分析を提供します。

フルレポートの例

癌レポートの例

バイオシミラー&バイオスーペリアタンパク質レポートの例

バイオシミラー&バイオスーペリアレポートの例

ワクチンレポートの例

その他の人気のあるレポートの例

目次
Product Code: LMDB0003

Abstract

Description

Flat-Rate Subscription to La Merie Publishing Reports

Subscription to this product provides access during one year to all existing and new reports produced by La Merie Publishing and listed in the online store. Among La Merie Publishing reports are Competitor Analysis reports as well as Full Reports. La Merie Publishing reports are continuously updated and new ones released. Reports can be searched for and identified in La Merie Publishing's online store. After purchase of the product, existing reports will be made available to the customer by e-mail delivery of the pdf reports. New reports will automatically be sent upon release of the report.

Features of the Flat-Rate Access to La Merie Publishing Reports:

  • Dynamic content (more than 50 updates and new releases per year)
  • Convenient e-mail delivery of pdf reports upon subscription and new release
  • Broad coverage of Oncology, Biosimilars, Antibodies, Proteins and Vaccines
  • Great savings over individual purchases

Reports of the Competitor Analysis Series deliver NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases and technologies provided in a tabular format and fully referenced. Each project described in the Competitor Analysis reports is specified for its Target or Mechanism of Action, Product Category, Indication, R&D Phase and Comment with a hyperlink leading to the source of information.

Full Reports provide in-depth description and analysis of targets, pipelines, companies and technologies.

Examples of Full Reports

  • Antibody Technologies and Attrition Rates - an industry analysis 2013
  • Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists - A Target Pipeline and Stakeholder Analysis 2012
  • Antibody-Drug Conjugates 2011 - real breakthrough still to come. A Technology, Stakeholder and R&D Pipeline Analysis
  • Coagulation Factors 2011 - who does meet the market needs? A Pipeline Assessment, Market Survey and Corporate Benchmark Analysis
  • Antibody Technology Companies 2010

Examples of Oncology Reprots

  • Antibody-Drug Conjugates (ADC)
  • c-MET/HGF Inhibitors
  • HDAC Inhibitors
  • Janus Kinase (JAK) Inhibitors
  • Novel Mitotic Kinase Inhibitors
  • PARP Inhibitors
  • PI3K-AKT-mTOR Inhibitors
  • Ras-Raf-MEK-ERK Inhibitors

Examples of Biosimilar & Biosuperior Protein Reports

  • Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors
  • Erythropoiesis Stimulating Agents (ESA)
  • Coagulation Factors
  • G-CSF and GM-CSF
  • Enzyme Replacement Therapies
  • FSH, LH & hCG: Assisted Reproductive Technologies (ART)
  • Interferon
  • Thrombopoiesis Stimulating Agents
  • Insulin
  • Human Growth Hormone
  • Thrombolytic Agents

Examples of Biosimilar & Biosuperior Antibody Reports

  • Biosimilar and Biosuperior Therapeutic Antibodies
  • CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors
  • Her2 Antibodies - Trastuzumab Biosimilars and Biobetters/Biosuperiors
  • VEGF Antibodies - Bevacizumab and Ranibizumab Biosimilars and Biosuperiors
  • EGF-R Antibodies -Biosimilars and Biosuperiors
  • TNF Antibodies -Biosimilars and Biosuperiors

Examples of Vaccine Reports

  • Herpes Virus Vaccines and Therapeutics
  • Pneumococcal and Streptococcal Vaccines
  • Tuberculosis Vaccines and Therapeutics
  • Malaria Vaccines & Therapeutics
  • CMV Vaccines & Therapeutics
  • Dengue Virus Vaccines & Therapeutics
  • RSV Vaccines & Therapeutics
  • Pseudomonar Aeruginosa Vaccines & Therapeutics
  • Staphylococcus aureus Vaccines & Therapeutics
  • Cancer Vaccines
  • HIV Vaccines
  • Hepatitis Vaccines
  • Influenza Vaccines
  • HPV Vaccines
  • Anthrax Vaccines & Therapeutics

Examples of Other Popular Reports

  • Toll-Like Receptor (TLR) Agonists & Antagonists
  • Cardiovascular Peptides
Back to Top